Details of the Drug-Related molecule(s) Interaction Atlas

Benserazide Drug Info

benserazide; Serazide; 322-35-0; Benseraszide; Benserazida; Benserazidum; Ro 4-4602; Ro 44602; DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide; Benserazidum [INN-Latin]; Benserazida [INN-Spanish]; Benserazide [USAN:INN:BAN]; DL-Seryltrihydroxybenzylhydrazine; C10H15N3O5; BRN 3984490; DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; CHEBI:64187; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Serine, 2-(2,3,4-trihydroxybenzyl)hyrazide, DL-; DL-serine 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide

Cross-matching ID

PubChem CID

2327

ChEBI ID

CHEBI:64187

CAS Number

CAS 322-35-0

TTD Drug ID

DMLU8NX

General Information of Drug (ID: DMLU8NX)

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aromatic-L-amino-acid decarboxylase (DDC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B6	DMDBZMV	Vitamin B6 deficiency	5B5D	Approved	[3]
Carbidopa	DMHRG8Q	Parkinson disease	8A00.0	Approved	[1]
Patrome	DM3H2U4	Parkinson disease	8A00.0	Phase 3	[4]
AV-201	DMDL9WU	Parkinson disease	8A00.0	Phase 2	[5]
VY-AADC	DMPSBTL	Parkinson disease	8A00.0	Phase 2	[6]
GT-AADC	DM8N3OQ	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[7]
PTC-AADC	DM9ZHE3	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[8]
ProSavin	DMJ42E6	Parkinson disease	8A00.0	Phase 1/2	[9]
OXB-102	DMXF9DM	Parkinson disease	8A00.0	Phase 1/2	[10]
VY-AADC01	DM0N71R	Parkinson disease	8A00.0	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Catechol O-methyltransferase (COMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[2]
Dobutamine	DMD1B8Z	Heart failure	BD10-BD13	Approved	[2]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[2]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[12]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[2]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[14]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[15]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatic-L-amino-acid decarboxylase (DDC)	TTN451K	DDC_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Catechol O-methyltransferase (COMT)	OTPWKTQG	COMT_HUMAN	Biotransformations	[2]

------------------------------------------------------------------------------------

References

1	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
2	Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol. 2001 Feb;59(2):393-402. doi: 10.1124/mol.59.2.393.
3	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
4	The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
5	UCSF report
6	Clinical pipeline report, company report or official report of Voyager Therapeutics.
7	Clinical pipeline report, company report or official report of PTC Therapeutics.
8	ClinicalTrials.gov (NCT04903288) An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects. U.S.National Institutes of Health.
9	Clinical pipeline report, company report or official report of Oxford BioMedica.
10	Clinical pipeline report, company report or official report of Oxford BioMedica.
11	Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-e50.
12	Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT. Sleep. 2010 Aug;33(8):1027-35. doi: 10.1093/sleep/33.8.1027.
13	Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
14	Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
15	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
16	Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. Parkinsonism Relat Disord. 2001 Apr;7(2):93-96. doi: 10.1016/s1353-8020(00)00027-4.
17	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.